Filing Details
- Accession Number:
- 0001415889-25-012056
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-05 21:52:22
- Reporting Period:
- 2025-05-02
- Filing Date:
- 2025-05-05
- Accepted Time:
- 2025-05-05 21:52:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1698262 | E. William Rote | C/O Travere Therapeutics, Inc. 3611 Valley Centre Drive, Ste 300 San Diego CA 92130 | Chief Research Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-05-02 | 4,920 | $0.00 | 103,439 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-05-05 | 3,198 | $21.05 | 100,241 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance-based restricted stock units | Disposition | 2025-05-02 | 4,920 | $0.00 | 4,920 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 4,920 | No | 4 | M | Direct |
Footnotes
- On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.
- Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Billionaire Hedge Funds
